JLJoanna Li

Joanna Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joanna Li has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Microdosimetry calculations in situ for clinically relevant photon sources and their correlation with the early DNA damage response

    by Mirta Dumančić, Jonathan Kalinowski, Victor D. Diaz‐Martinez, Joanna Li, Behnaz Behmand, Joseph M. DeCunha, Shirin A. Enger

    Background: Radiobiological data suggests variations in relative biological effectiveness (RBE) between clinically used photon‐based sources. A microdosimetric formalism using Monte Carlo (MC) methods can mechanistically describe the photon RBE. Experimentally derived RBE based on DNA double‐strand breaks () has been shown to scale with the microdosimetry quantity dose‐mean lineal energy (). Purpose: To calculate microdosimetric spectra for clinically relevant photon sources, spanning from soft x‐rays produced by a 50 kVp x‐ray source through various brachytherapy sources up to a 6 MV medical linac. Furthermore, we investigated the correlation between and of different photon sources. Methods: Photon sources simulated include low‐energy x‐rays (50 kVp), orthovoltage x‐rays (225 kVp), high‐dose‐rate brachytherapy sources ( 75 Se, 192 Ir and 60 Co), and a 6 MV medical linac. Secondary electron spectra at the cellular level were calculated for in vitro cell irradiation setups using Geant4 MC‐based packages, RapidBrachyMCTPS and RapidExternalBeam. The obtained spectra were used in MicroDose, a microdosimetry simulation software, to obtain microdosimetric quantities, including single‐event lineal energy () and specific energy () spectra, and dose‐mean and frequency‐mean quantities (, , , ). Uniform spherical targets (1–14 radius) and realistic HeLa and PC3 cell nucleus models were simulated using cell size data obtained from literature and nuclei size data from confocal microscopy imaging. Radiobiological experiments using foci quantified DNA double‐strand breaks for HeLa and PC3 cells after irradiations with 50 and 225 kVp, 192 Ir, and 6 MV linac, and was determined using 225 kVp as the reference. Results: The calculated () is within the 3.5–1.2 keV/ range (1.8–0.2 keV/) for 1 simulated target size between the lowest energy 50 kVp x‐ray source and the highest energy 6 MV linac source, respectively. For the HeLa and PC3 cell nuclei models based on microscopy data, () spans from 1.6 to 0.6 keV/ (0.7 to 0.2 keV/). When compared between different target sizes, () ranges from 3.5 to 1.0 (1.8–0.4) keV/ between 1 and 10 radius targets for the 50 kVp x‐ray source. A smaller change is observed for 6 MV linac, ranging from 1.2 to 0.5 keV/ and 0.23 to 0.22 keV/ for and , respectively. For the simulated 75 Se source currently under investigation, the calculated values are 11%–24% higher relative to those of 192 Ir in the range of target sizes between 1 and 14 in radius. for HeLa cells was 1.40.7 for 50 kVp x‐rays, 0.50.2 for 192 Ir, and 0.70.4 for 6 MV linac irradiations. For PC3 cells, was 1.30.6, 0.80.4 and 0.50.3 for 50 kVp, 192 Ir and 6 MV linac, respectively. Measured values are consistent with ratios of the corresponding photon sources for HeLa and PC3 nucleus models. Conclusions: Microdosimetric spectra strongly depend on the simulated energy of photon sources and target size, with and decreasing by a factor of 2–3 between diagnostic 50 kVp and 6 MV therapeutic x‐rays for target sizes from 1–14 in radius. The early damage indicates this stochastic change in energy density between various photon sources as the yields of foci per nucleus scale with of the source.


  • Open Access

    Monte Carlo-based dosimetry and optimization of a custom alpha cell irradiation setup

    by Maryam Rahbaran, Joanna Li, Shirin A Enger

    Objective. When combined with targeting agents, α-particle-emitting radionuclides show promise in treating hypoxic tumors and micrometastases. These radionuclides exhibit a high relative biological effectiveness (RBE), attributed to their high linear energy transfer, and induce complex DNA damage within targeted cells. However, most clinical experience and radiobiological data are derived from photon irradiation. To optimize α-particle-based treatments, further research is needed to refine their RBE estimates. This study aimed to characterize and optimize a custom in-vitro cell irradiation setup for α-particle RBE studies using 241Am through Monte Carlo simulations. Approach. A Geant4-based Monte Carlo simulation model was used to simulate a custom cell well setup. An 241Am (48 kBq) source was positioned beneath the well with an adjustable source-to-surface distance (SSD). The spectra of decay products was calculated with 6.5 × 10 9 simulated 241Am decay events. Simulations were conducted for SSD values of 2 mm, 5 mm, and 7 mm under three scenarios: (A) total dose rate from all decay products, (B) excluding γ-emissions, and (C) excluding secondary particles. Results were compared to published spectra and a published dose rate (0.1 Gy min−1) as validation. Main results. The validation dose rate was 0.1136 Gy min−1. Photons of 13.9–59.5 keV and α-particles of 5.39–5.48 MeV were observed. The dose inhomogeneity across the cells was around 30%, 10%, and 5% in the 2, 5, and 7 mm SSD setups, respectively. The corresponding total dose rates in cells for the three SSDs were 0.583, 0.146, and 0.0830 Gy min−1. The dose rate contributions were 90% from α-particles, less than 0.07% from γ-emissions, and 9%–10% from secondary particles. Significance. To accurately assess radiobiological effects, it is important to consider the full decay spectrum of radionuclides and their secondary particles in dosimetry calculations. These findings will aid in refining experimental setups for future in-vitro studies, contributing to more reliable RBE calculations.


  • Open Access

    Relative biological effectiveness of clinically relevant photon energies for the survival of human colorectal, cervical, and prostate cancer cell lines

    by Joanna Li, Naim Chabaytah, Joud Babik, Behnaz Behmand, Hamed Bekerat, Tanner Connell, Michael Evans, Russell Ruo, Te Vuong, Shirin Abbasinejad Enger

    Objective. Relative biological effectiveness (RBE) differs between radiation qualities. However, an RBE of 1.0 has been established for photons regardless of the wide range of photon energies used clinically, the lack of reproducibility in radiobiological studies, and outdated reference energies used in the experimental literature. Moreover, due to intrinsic radiosensitivity, different cancer types have different responses to radiation. This study aimed to characterize the RBE of clinically relevant high and low photon energies in vitro for three human cancer cell lines: HCT116 (colon), HeLa (cervix), and PC3 (prostate). Approach. Experiments were conducted following dosimetry protocols provided by the American Association of Physicists in Medicine. Cells were irradiated with 6 MV x-rays, an 192Ir brachytherapy source, 225 kVp and 50 kVp x-rays. Cell survival post-irradiation was assessed using the clonogenic assay. Survival fractions were fitted using the linear quadratic model, and survival curves were generated for RBE calculations. Main results. Cell killing was more efficient with decreasing photon energy. Using 225 kVp x-rays as the reference, the HCT116 RBESF0.1 for 6 MV x-rays, 192Ir, and 50 kVp x-rays were 0.89 ± 0.03, 0.95 ± 0.03, and 1.24 ± 0.04; the HeLa RBESF0.1 were 0.95 ± 0.04, 0.97 ± 0.05, and 1.09 ± 0.03, and the PC3 RBESF0.1 were 0.84 ± 0.01, 0.84 ± 0.01, and 1.13 ± 0.02, respectively. HeLa and PC3 cells had varying radiosensitivity when irradiated with 225 and 50 kVp x-rays. Significance. This difference supports the notion that RBE may not be 1.0 for all photons through experimental investigations that employed precise dosimetry. It highlights that different cancer types may not have identical responses to the same irradiation quality. Additionally, the RBE of clinically relevant photons was updated to the reference energy of 225 kVp x-rays.


  • ICOS-expressing Regulatory T Cells Influence the Composition of Antitumor CTL Populations

    by Nikoletta Diamantopoulos, Joanna Li, Antoine Bouchard, Loick Joumier, Saba Mohammaei, Vincent Panneton, Jinsam Chang, Mohan Malleshaiah, Woong-Kyung Suh

    The role of ICOS in antitumor T cell responses and overall tumor progression has been controversial. In this study, we compared tumor progression in mice lacking ICOS selectively in regulatory T (Treg) cells or in all T cells. Using an experimental melanoma lung metastasis model, we found that Treg cell–specific ICOS knockout reduces the overall tumor burden compared with Cre control mice, with increased CD4+-to-Treg cell and CD8+-to-Treg cell ratios in the tumor. In contrast, there was no difference in the tumor burden in mice lacking ICOS in all of the T cell compartments. This suggests a dual role of ICOS costimulation in promoting protumor and antitumor T cell responses. Consistent with reduced tumor burden, we found that Treg cell–specific deletion of ICOS leads to an increase of CD8+ CTLs that express high levels of granzyme B and perforin. Moreover, single-cell transcriptome analysis revealed an increase of Ly108+Eomeshi CD8+ T cells at the cost of the Ly108+T-bethi subset in Treg cell–specific knockout mice. These results suggest that ICOS-expressing Treg cells suppress the CTL maturation process at the level of Eomes upregulation, a critical step known to drive perforin expression and cytotoxicity. Collectively, our data imply that cancer immunotherapies using ICOS agonist Abs may work better in Treg cell–low tumors or when they are combined with regimens that deplete tumor-infiltrating Treg cells.


  • ICOS-Deficient Regulatory T Cells Can Prevent Spontaneous Autoimmunity but Are Impaired in Controlling Acute Inflammation

    by Jinsam Chang, Antoine Bouchard, Yasser Bouklouch, Vincent Panneton, Joanna Li, Nikoletta Diamantopoulos, Saba Mohammaei, Roman Istomine, Fernando Alvarez, Ciriaco A Piccirillo, et al.

    ICOS is induced in activated T cells and its main role is to boost differentiation and function of effector T cells. ICOS is also constitutively expressed in a subpopulation of Foxp3+ regulatory T cells under steady-state condition. Studies using ICOS germline knockout mice or ICOS-blocking reagents suggested that ICOS has supportive roles in regulatory T (Treg) cell homeostasis, migration, and function. To avoid any compounding effects that may arise from ICOS-deficient non–Treg cells, we generated a conditional knockout system in which ICOS expression is selectively abrogated in Foxp3-expressing cells (ICOS FC mice). Compared to Foxp3-Cre control mice, ICOS FC mice showed a minor numerical deficit of steady-state Treg cells but did not show any signs of spontaneous autoimmunity, indicating that tissue-protective Treg populations do not heavily rely on ICOS costimulation. However, ICOS FC mice showed more severe inflammation in oxazolone-induced contact hypersensitivity, a model of atopic dermatitis. This correlated with elevated numbers of inflammatory T cells expressing IFN-γ and/or TNF-α in ICOS FC mice compared with the control group. In contrast, elimination of ICOS in all T cell compartments negated the differences, confirming that ICOS has a dual positive role in effector and Treg cells. Single-cell transcriptome analysis suggested that ICOS-deficient Treg cells fail to mature into T-bet+CXCR3+ “Th1-Treg” cells in the draining lymph node. Our results suggest that regimens that preferentially stimulate ICOS pathways in Treg cells might be beneficial for the treatment of Th1-driven inflammation. Key Points ICOS-deficient Treg cells can suppress spontaneous autoimmunity. ICOS-deficient Treg cells show impaired differentiation of Th1-Treg cells.


  • Open Access

    Hippo Signal Transduction Mechanisms in T Cell Immunity

    by Antoine Bouchard, Mariko Witalis, Jinsam Chang, Vincent Panneton, Joanna Li, Yasser Bouklouch, Woong-Kyung Suh

    Bouchard A, et al. Immune Netw. 2020 Oct;20(5):e36. https://doi.org/10.4110/in.2020.20.e36